About the event
Join us in Glasgow for ISPOR Europe 2025, the premier global conference in Europe for Health Economics and Outcomes Research (HEOR). As a proud ISPOR Mission Partner, we’re excited to connect with global healthcare leaders to advance the future of healthcare together. Be sure to visit us at booth 712!
Speaker sessions
Educational symposium
Navigating Global Policy Shifts: Implications for Europe’s Pharmaceutical Pricing, Market Access, and HTA Landscape
Date: Monday, 10 November, 2025
Time: 3:15pm – 4:15pm
Moderator: Casper Paardekooper, Vintura
Speakers: Neil Grubert, Independent Global Market Access Consultant; Anja Schiel, Norwegian Medicinal Products Agency; Christoph Glaetzer, Johnson and Johnson
Time: 3:15pm – 4:15pm
Moderator: Casper Paardekooper, Vintura
Speakers: Neil Grubert, Independent Global Market Access Consultant; Anja Schiel, Norwegian Medicinal Products Agency; Christoph Glaetzer, Johnson and Johnson
Issue panel
Integrating AI Into Market Access Workflows
Date: Monday, 10 November 2025
Time: 10:15pm-11:15pm
Moderator: David Ringger
Speakers: Philippe Habets, EvidenceHunt; Eelko den Breejen, Pfizer; Andreas Altemark, Roche Diagnostics
Time: 10:15pm-11:15pm
Moderator: David Ringger
Speakers: Philippe Habets, EvidenceHunt; Eelko den Breejen, Pfizer; Andreas Altemark, Roche Diagnostics
Workshop
Navigating the Global Pricing Policy Landscape and Leveraging AI for Strategic Insight
Date: Tuesday, 11 November, 2025
Time: 10:15am - 11:15am
Speakers: David Ringger, Cencora; Neil Grubert, Independent Global Market Access Consultant; Casper Paardekooper, Vintura; Leanna Baker Williams, Cencora
Time: 10:15am - 11:15am
Speakers: David Ringger, Cencora; Neil Grubert, Independent Global Market Access Consultant; Casper Paardekooper, Vintura; Leanna Baker Williams, Cencora
Issue panel
Accelerating Patient Access to Innovations in Europe: Is it Possible to Integrate the JCA into Diverse HTA systems?
Date: Tuesday, 11 November 2025
Time: 1:45pm-2:45pm
Moderator: Ruairi O’Donnell
Speakers: Anja Schiel, Norwegian Medicines Agency; James Ryan, AstraZeneca; Rod Taylor
Time: 1:45pm-2:45pm
Moderator: Ruairi O’Donnell
Speakers: Anja Schiel, Norwegian Medicines Agency; James Ryan, AstraZeneca; Rod Taylor
Issue panel
Embedding the Patient Voice within EU HTA: How Can We Balance Inclusivity, Representativeness and Scientific Rigour?
Date: Wednesday 12 November, 2025
Time: 10:00-11:00am
Moderator: Ruairi O’Donnell
Speakers: Matteo Scarabelli, EFPIA; Antonella M Cardone, Cancer Patients Europe; Justin Doan, Pfizer
Time: 10:00-11:00am
Moderator: Ruairi O’Donnell
Speakers: Matteo Scarabelli, EFPIA; Antonella M Cardone, Cancer Patients Europe; Justin Doan, Pfizer
Don’t miss our poster presentations during ISPOR Europe 2025:
We’re thrilled to present groundbreaking research at ISPOR Europe! This year, our work spans a wide range of pressing healthcare topics, including global pricing dynamics, policy insights, cost-effectiveness evaluations, advancements in artificial intelligence, and health technology assessment (HTA) evolution. We’ll also spotlight transformative solutions and the latest breakthroughs in health economics and outcomes research (HEOR). It’s an honor to contribute to these vital conversations and share our findings with the global community. Don’t miss the chance to join us and engage in shaping the future of healthcare.
- Care dependency and sick leave patterns in early Alzheimer's disease: A retrospective claims data analysis in Germany
Adapting to change: Analysis of trend estimation in AMNOG dossiers under revised G-BA guidelines
- Evaluating the effectiveness of interventions to reduce gender disparities in healthcare: An overview of literature reviews
- Economic burden and healthcare resource utilization of metabolic dysfunction-associated steatohepatitis (MASH) in Germany: A claims data analysis
- Feasibility evaluation of claims database: Best practices and case study for a comparative analysis of robotic-assisted colorectal surgery in Germany
- From admission to discharge: Understanding the transplant patient journey with German statutory health insurance claims data
- Evaluating the performance of an artificial intelligence (AI)-powered tool for assessing quality of published economic evaluations: A comparison with human reviewers using the Drummond checklist
- Global pricing meets domestic policy: Analyzing the financial impact of the most-favored nation approach on the United States’ medicine prices
- Hospital mortality in Germany – Analysis of German hospital data from 2000 to 2019
- Quality and impact of real-world data in chronic disease research: Insights from retrospective studies using the Hospital Episode Statistics (HES) database
- Medication used in indolent systemic mastocytosis (ISM) in Germany prior to Avapritinib approval
- Trends in glucagon-like peptide-1 (GLP-1) receptor agonist prescribing in England: A data analysis using NHS prescription episodes statistics (PES)
- The efficacy of multi-level pairwise meta-regression in the mitigation of aggregation bias: A simulation study
- Utilization and patient characteristics of robotic-assisted colorectal surgery in Germany: A claims data analysis
- Utilization of real-world evidence (RWE) in AMNOG dossiers following the 2024 G-BA revision of module 3 requirements
- Unlocking insights in prescription data in England: The power of the prescribing episode statistics (PES) database
- Insights from a French post-marketing authorization early access (post-MA EA) mechanism: Projecting clinical and economic benefits of neoadjuvant Nivolumab plus platinum-based chemotherapy (PDC) in resectable non-small lung cancer (NSCLC)
- Cost-effectiveness analysis of Dostarlimab plus carboplatin-paclitaxel in primary advanced or recurrent endometrial cancer with deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) in France
- A cost-effectiveness evaluation of Blinatumomab use in the measurable residual disease-negative remission state to treat adults with Philadelphia-chromosome-negative B-cell acute lymphoblastic leukemia in France
- Societal and economic impact of long-acting injectable buprenorphine (LAIB) compared with standard opioid substitution therapy (OST) in France
- The impact of Burosumab on the clinical and economic burden of x-linked hypophosphatemia in adult patients in France
- Organizational budget impact analysis of the port-delivery-platform with SUSVIMO in age-related macular degeneration (AMD) in France
- Persistence of anticholinergic agents in patients with overactive bladder: A cohort study from the French National Health Insurance Claims Database (SNDS)
- Urinary dysfunction (UD) is a common comorbidity in people with multiple sclerosis (PwMS), negatively affecting quality of life and increasing the risk of complications when insufficiently diagnosed or managed
- Psychotropic medications for patients with treatment-resistant depression in France
- Evaluation of the societal impact of Emicizumab in France since its market authorization: Budget impact from 2018 to 2024
- Budget impact analysis of the EPOCA telemonitoring system for elderly patients in France
- Balancing fit and accuracy: Evaluating survival model projections with immature data in health technology assessments
- Exploring Nordic real-world evidence sources for a PICO assessment of a hypothetical oncology drug and medical device product
- A comparative analysis of the Nordic market access pathways for medical devices
- Inducing labor in Denmark – A descriptive study
Cencora solution
EU Health Technology Assessment (HTA) consulting
As the European Union takes bold strides towards harmonizing and enhancing its healthcare landscape, the implementation of the Joint Clinical Assessment (JCA) stands as a pivotal moment. At Cencora, we help companies at all stages of the EU HTA journey, from early evidence to post-JCA implementation at the national level.
Catch up on our latest insights
Webinar
Fit-for-Purpose RWD: An Integral Part of Evidence Planning
Evidence planners in the life sciences are increasingly adopting Integrated Evidence Planning (IEP) to meet the diverse needs of stakeholders, with real-world evidence (RWE) being vital for demonstrating the safety and value of products beyond traditional clinical trials. The emergence of new global data sources, such as patient registries and electronic health records, complicates the selection of appropriate real-world data (RWD) for research objectives.
Article
HTA Quarterly Fall 2025
In this edition, we continue our three-part series on France’s Early Access Program, exploring evolving evidence requirements and their implications for managing clinical and financial uncertainties. We also turn our attention to North America, examining the recent establishment of state-level Prescription Drug Affordability Boards to address high prescription drug prices in the U.S., and how the Canadian Drug Agency incorporates patient perspectives into health technology appraisals, shaping the data used for evaluations.
Meet with us at ISPOR Europe
Our consultative approach and extensive reach across healthcare give us access to the best insights in the industry - insights we leverage to help commercialization challenges for our partners and patients they serve. Schedule a meeting with our team at ISPOR to learn more.
